# Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures

> **NCT04970212** · — · COMPLETED · sponsor: **Techsomed Medical Technologies LTD** · enrollment: 65 (actual)

## Conditions studied

- Carcinoma, Hepatocellular
- Metastatic Liver Cancer

## Interventions

- **DEVICE:** BioTraceIO Lite

## Key facts

- **NCT ID:** NCT04970212
- **Lead sponsor:** Techsomed Medical Technologies LTD
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-24
- **Primary completion:** 2022-10-08
- **Final completion:** 2022-10-08
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04970212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04970212, "Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04970212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*